DE60334316D1 - Frpb proteinmutante und verfahren zur erneuten faltung - Google Patents

Frpb proteinmutante und verfahren zur erneuten faltung

Info

Publication number
DE60334316D1
DE60334316D1 DE60334316T DE60334316T DE60334316D1 DE 60334316 D1 DE60334316 D1 DE 60334316D1 DE 60334316 T DE60334316 T DE 60334316T DE 60334316 T DE60334316 T DE 60334316T DE 60334316 D1 DE60334316 D1 DE 60334316D1
Authority
DE
Germany
Prior art keywords
frpb protein
removal procedure
protein mutant
frpb
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60334316T
Other languages
German (de)
English (en)
Inventor
Ralph Biemans
Philippe Denoel
Christiane Feron
Carine Goraj
Jeroen Kortekaas
Jan Poolman
Jan Tommassen
Vincent Weynants
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
TECHNOLOGY FOUNDATION STICHTIN
Universiteit Utrecht
Original Assignee
GlaxoSmithKline Biologicals SA
TECHNOLOGY FOUNDATION STICHTIN
Rijksuniversiteit Utrecht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA, TECHNOLOGY FOUNDATION STICHTIN, Rijksuniversiteit Utrecht filed Critical GlaxoSmithKline Biologicals SA
Application granted granted Critical
Publication of DE60334316D1 publication Critical patent/DE60334316D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
DE60334316T 2002-08-30 2003-08-28 Frpb proteinmutante und verfahren zur erneuten faltung Expired - Lifetime DE60334316D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0220199.4A GB0220199D0 (en) 2002-08-30 2002-08-30 Mutant protein and refolding method
PCT/EP2003/009634 WO2004020463A2 (en) 2002-08-30 2003-08-28 Mutant protein and refolding method

Publications (1)

Publication Number Publication Date
DE60334316D1 true DE60334316D1 (de) 2010-11-04

Family

ID=9943242

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60334316T Expired - Lifetime DE60334316D1 (de) 2002-08-30 2003-08-28 Frpb proteinmutante und verfahren zur erneuten faltung

Country Status (10)

Country Link
US (1) US20060141563A1 (https=)
EP (1) EP1572729B1 (https=)
JP (1) JP2006516183A (https=)
AT (1) ATE481983T1 (https=)
AU (1) AU2003287945A1 (https=)
CA (1) CA2495086A1 (https=)
DE (1) DE60334316D1 (https=)
ES (1) ES2351598T3 (https=)
GB (1) GB0220199D0 (https=)
WO (1) WO2004020463A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
US8398983B2 (en) 2005-06-27 2013-03-19 Glaxosmithkline Biologicals, S.A. Immunogenic composition
DE602007003596D1 (de) * 2006-06-12 2010-01-14 Glaxosmithkline Biolog Sa Impfstoff
JP5568017B2 (ja) * 2008-12-25 2014-08-06 一般財団法人化学及血清療法研究所 組換え鶏伝染性コリーザワクチン及びその製造方法
BR112013005626B1 (pt) * 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
US9322011B2 (en) * 2010-09-28 2016-04-26 Abera Bioscience Ab Fusion protein for secretory protein expression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265567B1 (en) * 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
US6084076A (en) * 1995-12-21 2000-07-04 Ajinomoto Co., Inc. Method of refolding human activin A
PL216780B1 (pl) * 2000-01-25 2014-05-30 Univ Queensland Of Santa Lucia Wyizolowane białka zawierające konserwatywne obszary antygenu powierzchniowego NhhA z Neisseria meningitidis, białka fuzyjne, kompozycja farmaceutyczna, przeciwciało monoklonalne lub wiążący antygen fragment przeciwciała monoklonalnego, wyizolowany kwas nukleinowy, konstrukt ekspresyjny, komórka gospodarza, sposób wytwarzania rekombinowanego białka, sposób wykrywania N. meningitidis w próbce biologicznej, sposób diagnozowania zakażenia N. meningitidis oraz sposób wykrywania N. meningitidis w próbce biologicznej uzyskanej od pacjenta oraz zastosowanie wyizolowanego białka, białka fuzyjnego i konstruktu ekspresyjnego

Also Published As

Publication number Publication date
US20060141563A1 (en) 2006-06-29
EP1572729A2 (en) 2005-09-14
AU2003287945A8 (en) 2004-03-19
CA2495086A1 (en) 2004-03-11
AU2003287945A1 (en) 2004-03-19
WO2004020463A2 (en) 2004-03-11
JP2006516183A (ja) 2006-06-29
ATE481983T1 (de) 2010-10-15
WO2004020463A3 (en) 2005-08-18
GB0220199D0 (en) 2002-10-09
ES2351598T3 (es) 2011-02-08
EP1572729B1 (en) 2010-09-22

Similar Documents

Publication Publication Date Title
EP2444809A3 (en) Methods of generating and screening for proteases with altered specificity
EP1490677A4 (en) COMPUTER METHOD FOR DESIGNING ENZYMES FOR THE INCORPORATION OF AMINO ACID ANALOGUES INTO PROTEINS
DE60330376D1 (de) Defructosylierungsverfahren
DE60309087D1 (de) System und Methode zur Reglung von optischen Verstärkern
DE602004023229D1 (de) Mais metallothionen promoter 2 und methoden zur verwendung
SG149000A1 (en) Gag binding proteins
DE69932845D1 (de) Methoden zur quantifizierung von hla-dr und cd11b
EP1482858A4 (en) PROCESS FOR THE REPARATION OF ANEURYSMS
ATE302844T1 (de) Verfahren zur aufreinigung eines enzyms und hiernach hergestelltes, aufgereinigtes enzym sowie verwendung des enzyms
ATE433441T1 (de) Verfahren und vorrichtung zur herstellung von percarbonsäure
ATE336597T1 (de) Verfahren zur gewinnung von gold
DE60330099D1 (de) Verfahren und Anordnungen zur Herstellung, Feststellung und Übertragung von Identifikatoren
DE60334316D1 (de) Frpb proteinmutante und verfahren zur erneuten faltung
ATE492631T1 (de) Verwendung von mutationen zur verbesserung von aspergillus-phytasen
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
DE60301283D1 (de) Verfahren zur Bestimmung von Biopolymeren
DE60325194D1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
ATA19172002A (de) Verfahren zum einbringen und verblasen von gesteinsstaub sowie vorrichtung zur durchführung dieses verfahrens
NO20050599L (no) Fremgangsmate for a anrike og spore patologisk modifiserte prion-proteiner (PRPsc)
DE60336205D1 (de) Verfahren zur Betriebsmodusnotifizierung.
DE60317620D1 (de) Methode zur Bestimmung von UDP-GlcNac
ATE392480T1 (de) Verfahren zur vorhersage der expressionseffizienz in zellfreien expressionssystemen
ATE451457T1 (de) Verfahren zur dipeptidherstellung
ATE269905T1 (de) Verfahren zur herstellung von proteinen in wirtszellen unter verwendung von chaperoninen
DK1427840T3 (da) Enzymatisk fremgangsmåde til enantiomer-adskillelse af aminosyrer